Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1985 1
1992 1
1996 1
1997 1
1998 2
1999 1
2001 1
2005 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997.
Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam JJ, Simonian NA, Campion MK, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Weistock-Guttman B, Whitham RH; Multiple Sclerosis Collaborative Research Group. Rudick RA, et al. Among authors: coats me. Neurology. 2001 Dec;57(12 Suppl 5):S25-30. Neurology. 2001. PMID: 11902591 No abstract available.
Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Goodkin DE, Priore RL, Wende KE, Campion M, Bourdette DN, Herndon RM, Fischer JS, Jacobs LD, Cookfair DL, Rudick RA, Richert JR, Salazar AM, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Whitham RH, et al. Goodkin DE, et al. Among authors: coats me. Mult Scler. 1998 Dec;4(6):480-6. doi: 10.1177/135245859800400604. Mult Scler. 1998. PMID: 9987756
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al. Jacobs LD, et al. Among authors: coats me. Ann Neurol. 1996 Mar;39(3):285-94. doi: 10.1002/ana.410390304. Ann Neurol. 1996. PMID: 8602746 Clinical Trial.
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam JJ, Simonian NA, Campion MK, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Whitham RH, et al. Rudick RA, et al. Among authors: coats me. Neurology. 1997 Aug;49(2):358-63. doi: 10.1212/wnl.49.2.358. Neurology. 1997. PMID: 9270562 Clinical Trial.
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).
Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE 3rd, Cookfair DL, Simon JH, Jacobs LD. Rudick RA, et al. Among authors: coats me. Neurology. 1998 May;50(5):1266-72. doi: 10.1212/wnl.50.5.1266. Neurology. 1998. PMID: 9595973 Clinical Trial.
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, Herndon RM, Salazar AM, Fischer JS, Granger CV, Goodkin DE, Simon JH, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munchsauer FE, O'Reilly K, Priore RL, Whitham RH, et al. Rudick RA, et al. Among authors: coats me. J Neuroimmunol. 1999 Jan 1;93(1-2):8-14. doi: 10.1016/s0165-5728(98)00174-x. J Neuroimmunol. 1999. PMID: 10378864 Clinical Trial.